Pharvaris N.V. (PHVS)
NASDAQ:PHVS
Want to see PHVS full AI Analyst Report?
PHVS Stock Chart & Stats
$28.58
-$0.46(-2.39%)
At close: 4:00 PM EST
$28.58
-$0.46(-2.39%)
Day’s Range― - ―
52-Week Range$15.91 - $33.33
Previous CloseN/A
Volume14.65K
Average Volume (3M)363.52K
Market Cap
$2.01B
Enterprise Value$1.55B
Total Cash (Recent Filing)$246.96M
Total Debt (Recent Filing)$738.89K
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Aug 19, 2026EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.83
Shares Outstanding69,282,486
10 Day Avg. Volume290,498
30 Day Avg. Volume363,517
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)5.15
Price to Sales (P/S)0.00
P/FCF Ratio-10.18
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.52K
Enterprise Value/Ebitda-9.10
Forecast
1Y Price Target
$49.10Price Target Upside71.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.66
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressCompletion of enrollment in the Phase 3 prophylaxis study reduces clinical risk and positions the program for a pivotal data readout that could drive valuation.
Commercial Readiness And FinancingSufficient liquidity and accelerating commercial preparations enhance the company's ability to execute a launch and support market uptake if approvals are obtained.
Regulatory PathwayPositive on-demand study results and supportive long-term trial data strengthen the case for a new drug application for the oral on-demand formulation, lowering regulatory uncertainty.
Bears Say
Competitive Efficacy ExpectationsRising market expectations for oral therapy efficacy increase the performance bar deucrictibant must clear to compete with established injectables, heightening development and approval risk.
Conflicts Of InterestResearch firms' business relationships with covered companies may introduce conflicts that could bias reports and affect investor confidence.
Execution RiskReliance on key regulatory submissions and pivotal data readouts to realize commercial potential creates execution risk that could pressure the stock if milestones are delayed or unfavorable.
Pharvaris News
PHVS FAQ
What was Pharvaris N.V.’s price range in the past 12 months?
Pharvaris N.V. lowest stock price was $15.91 and its highest was $33.33 in the past 12 months.
What is Pharvaris N.V.’s market cap?
Pharvaris N.V.’s market cap is $2.01B.
When is Pharvaris N.V.’s upcoming earnings report date?
Pharvaris N.V.’s upcoming earnings report date is Aug 19, 2026 which is in 77 days.
How were Pharvaris N.V.’s earnings last quarter?
Pharvaris N.V. released its earnings results on May 12, 2026. The company reported $0.685 earnings per share for the quarter, beating the consensus estimate of N/A by $0.685.
Is Pharvaris N.V. overvalued?
According to Wall Street analysts Pharvaris N.V.’s price is currently Undervalued.
Does Pharvaris N.V. pay dividends?
Pharvaris N.V. does not currently pay dividends.
What is Pharvaris N.V.’s EPS estimate?
Pharvaris N.V.’s EPS estimate is -0.77.
How many shares outstanding does Pharvaris N.V. have?
Pharvaris N.V. has 69,282,486 shares outstanding.
What happened to Pharvaris N.V.’s price movement after its last earnings report?
Pharvaris N.V. reported an EPS of $0.685 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5.408%.
Which hedge fund is a major shareholder of Pharvaris N.V.?
Currently, no hedge funds are holding shares in PHVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharvaris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.10 (71.80% Upside)
$49.10 (71.80% Upside)
Blogger Sentiment
Bullish
PHVS Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.30%
12-Months-Change
Fundamentals
Return on Equity
-67.40%
Trailing 12-Months
Asset Growth
11.71%
Trailing 12-Months
Company Description
Pharvaris N.V.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
PHVS Stock 12 Month Forecast
Average Price Target
$49.10
▲(71.80% Upside)
Technical Analysis
Ownership Overview
1.49% Insiders
7.72% Mutual Funds
65.14% Other Institutional Investors
24.46% Public Companies and
Individual Investors